ZIOPHARM Oncology, Inc. (ZIOP) announced positive preliminary overall survival, or OS, data from its randomized, controlled Phase 2 trial of palifosfamide plus doxorubicin versus doxorubicin alone, or PICASSO, in patients with unresectable or metastatic soft tissue sarcoma.
An analysis of the OS data conducted according to the statistical analysis plan, with greater than 70% of events occurring and follow-up of 33 months, showed a meaningfully positive trend favoring the palifosfamide arm. This well-controlled trial is demonstrating longer than expected survival in a difficult to treat population, the company noted.
ZIOPHARM stated that at 2-years after starting treatment, around 40% of subjects treated with palifosfamide are alive and 30% in the control arm treated with doxorubicin are alive, compared to an expected 25% based on randomized data.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.